Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3

Status

Terminated 6Completed 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 2Other solid neoplasm 1Head & Neck 1

Conditions

Solid Tumor, Adult 1Pyloric Stenosis, Hypertrophic 1Nasopharyngeal Carcinoma 1Lymphoproliferative Disorders 1Epstein-Barr Virus Infections 1EBV Lymphomas 1Advanced Cancer 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Valganciclovir × Clear all
NCT06391918 2026-03-13

Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors

GenVivo, Inc.

Phase 1 Terminated
37 enrolled
Other solid neoplasm

Solid Tumor, Adult

NCT05011058 2025-07-28

NAVAL-1

Viracta Therapeutics, Inc.

Phase 2 Terminated
102 enrolled 28 charts

Epstein-Barr Virus Infections, Pyloric Stenosis, Hypertrophic

NCT05166577 2025-03-12

Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

Viracta Therapeutics, Inc.

Phase 1 Terminated
26 enrolled 23 charts
Head & Neck

Nasopharyngeal Carcinoma

NCT06302140 2025-01-20

A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers

Viracta Therapeutics, Inc.

Phase 1 Terminated
8 enrolled

Advanced Cancer

NCT00917826 2011-08-01

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

HemaQuest Pharmaceuticals Inc.

Phase 2 Terminated
1 enrolled
Lymphoid

EBV Lymphomas

NCT00992732 2011-08-01

Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders

HemaQuest Pharmaceuticals Inc.

Phase 2 Terminated
1 enrolled
Lymphoid

Lymphoproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡